Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Avalo Therapeutics Inc (AVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AVTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $29.88
1 Year Target Price $29.88
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -94.18% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.76M USD | Price to earnings Ratio 0.04 | 1Y Target Price 29.88 |
Price to earnings Ratio 0.04 | 1Y Target Price 29.88 | ||
Volume (30-day avg) 8 | Beta 0.71 | 52 Weeks Range 3.39 - 16.00 | Updated Date 06/30/2025 |
52 Weeks Range 3.39 - 16.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 118.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16556.01% | Operating Margin (TTM) -11408.39% |
Management Effectiveness
Return on Assets (TTM) -23.98% | Return on Equity (TTM) 67.82% |
Valuation
Trailing PE 0.04 | Forward PE - | Enterprise Value -72272424 | Price to Sales(TTM) 117.36 |
Enterprise Value -72272424 | Price to Sales(TTM) 117.36 | ||
Enterprise Value to Revenue 2.74 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 10827600 | Shares Floating 3809482 |
Shares Outstanding 10827600 | Shares Floating 3809482 | ||
Percent Insiders 6.39 | Percent Institutions 76.24 |
Analyst Ratings
Rating 3 | Target Price 29.88 | Buy 1 | Strong Buy 6 |
Buy 1 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avalo Therapeutics Inc
Company Overview
History and Background
Avalo Therapeutics, Inc., formerly Cerecor Inc., is a clinical-stage biopharmaceutical company focused on precision medicines for patients with significant unmet clinical need in immunology, hematology, and oncology. The company was founded in 2011 as Cerecor and has undergone significant transformations including acquisitions and a name change to reflect its current focus.
Core Business Areas
- Hematology: Focuses on developing therapies for hematological disorders.
- Immunology: Developing therapies for immune-mediated diseases.
- Oncology: Developing therapies for cancer treatments.
Leadership and Structure
Avalo Therapeutics is led by a management team with expertise in drug development and commercialization. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- AVTX-801 (Galactosemia): AVTX-801 is an investigational therapy for Galactosemia, a rare genetic metabolic disorder. Market share data is not publicly available. Competitors are primarily focused on dietary management and supportive care, with limited approved therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Precision medicine is a growing area, focusing on targeted therapies based on individual patient characteristics.
Positioning
Avalo Therapeutics is positioned as a precision medicine company focusing on rare and orphan diseases. Its competitive advantage lies in its targeted approach and potentially novel therapies.
Total Addressable Market (TAM)
The total addressable market for rare diseases is substantial, estimated to be in the billions of dollars. Avalo Therapeutics aims to capture a portion of this TAM with its pipeline of precision medicines.
Upturn SWOT Analysis
Strengths
- Focus on precision medicine
- Pipeline of targeted therapies
- Experienced management team
- Focus on rare diseases with unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Regulatory risk
- Competition from larger pharmaceutical companies
Opportunities
- Partnerships and collaborations
- Expansion of pipeline through acquisitions or licensing
- Positive clinical trial results
- Orphan drug designations and expedited regulatory pathways
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from existing therapies
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- LLY
- VRTX
- BMY
Competitive Landscape
Avalo Therapeutics faces intense competition from larger pharmaceutical companies with greater resources. Its success depends on its ability to develop and commercialize innovative therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, reflecting the company's strategic shifts and clinical trial progress.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates are subject to change.
Recent Initiatives: Recent initiatives include advancing its pipeline of precision medicines and exploring strategic partnerships.
Summary
Avalo Therapeutics is a clinical-stage biopharmaceutical company with a focus on precision medicine and rare diseases. The company has a promising pipeline but faces challenges typical of the biotechnology industry, including clinical trial risk and competition. Avalo's success hinges on successful clinical development and commercialization of its therapies, as well as strategic partnerships to bolster its financial position. Investors should be aware of the high-risk, high-reward nature of investing in such companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Databases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avalo Therapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2015-11-13 | President, CEO & Director Dr. Garry A. Neil M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.avalotx.com |
Full time employees 23 | Website https://www.avalotx.com | ||
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.